FREE Case Evaluation: 1-888-887-3117
Claims against tylenol have emerged as a significant legal issue, with hundreds of lawsuits alleging that manufacturers failed to warn pregnant women that acetaminophen use could increase the risk of autism and ADHD in their children. Here's what you need to know:
Key Points About Tylenol Legal Claims:
The legal battle began in earnest in September 2022, when families started filing lawsuits nationwide. These claims were consolidated into a Multidistrict Litigation (MDL) in the Southern District of New York before Judge Denise Cote. By late 2024, over 500 cases had been filed, all alleging that acetaminophen manufacturers knew or should have known about potential risks to fetal brain development but failed to provide adequate warnings to consumers.
In August 2024, Judge Cote issued a 148-page ruling that barred the plaintiffs' expert witnesses from testifying, finding they "failed to support their conclusions with scientific evidence." This effectively dismissed the federal cases, though families are now appealing to the Second Circuit Court of Appeals and pursuing claims in state courts.
The stakes are high. Texas Attorney General Ken Paxton filed a lawsuit in 2025 accusing manufacturers of "deceptively marketing Tylenol to pregnant mothers despite knowing that early exposure to acetaminophen increases the risk of autism and other disorders in children." Meanwhile, the FDA has initiated a label change process to reflect potential neurological risks, though the agency emphasizes that no causal relationship has been definitively established.
Beyond autism and ADHD claims, Tylenol has faced other legal challenges over the years, including lawsuits alleging liver damage from acetaminophen overdose. These cases highlight ongoing concerns about product safety and whether manufacturers have adequately communicated risks to consumers.
I'm Tim Burd, CEO of Justice Hero, where we've helped connect thousands of individuals with qualified legal representation for mass tort cases, including claims against tylenol. Through my work with Mass Tort Strategies, I've seen how complex pharmaceutical litigation can be for families seeking answers and justice.
Claims against tylenol helpful reading:
The heart of the recent claims against Tylenol manufacturers revolves around a critical accusation: the alleged failure to warn pregnant mothers about potential risks associated with using acetaminophen during pregnancy. Plaintiffs assert that manufacturers like Johnson & Johnson (and its spin-off Kenvue) and major retailers such as Walmart, CVS, Walgreens, Costco, Rite Aid, Safeway, and Target deceptively marketed Tylenol as safe for pregnant women, despite having knowledge that prenatal exposure to acetaminophen might increase the risk of neurodevelopmental disorders like Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD) in children.
These lawsuits contend that a responsible manufacturer or retailer should have provided adequate warnings on their product labels or in their marketing materials. This lack of warning, they argue, prevented expectant mothers from making informed decisions about their medication use, potentially leading to adverse health outcomes for their children.
The scientific community has been struggling with the potential link between prenatal acetaminophen exposure and neurodevelopmental disorders for some time. Numerous studies have explored this association, with some indicating a correlation.
For instance, multiple large-scale cohort studies, including the Nurses’ Health Study II and the Boston Birth Cohort, have identified an association. A notable 2019 Johns Hopkins study, published in JAMA, analyzed acetaminophen levels in newborns’ umbilical cord blood. Researchers found that children with the highest levels of acetaminophen were approximately three times more likely to be diagnosed with autism and 2.26 times more likely to have an ADHD diagnosis compared to those with the lowest levels, suggesting a potential dose-response relationship.
Further supporting these concerns, a 2018 article in the American Journal of Epidemiology reviewed studies involving over 132,000 mother-child pairs, concluding that acetaminophen exposure during pregnancy might lead to a 20-30% increased risk for neurodevelopmental disorders. A 2015 Danish National Research Foundation study of over 64,000 children found an increased risk of ASD with hyperkinetic symptoms when mothers used acetaminophen during pregnancy, with the risk nearly doubling for longer durations of use. More recently, a 2022 study in PLoS One indicated that children whose mothers used acetaminophen during pregnancy were more likely to experience attention and sleep problems at age three.
These studies propose potential mechanisms for this link, such as acetaminophen crossing the placental barrier and affecting fetal brain development or altering the immune system. For more in-depth information on this complex topic, we encourage you to explore our comprehensive resource on the Tylenol and Autism Lawsuit.
While the aforementioned studies suggest an association, establishing a definitive causal relationship between prenatal acetaminophen use and neurodevelopmental disorders is a significant scientific challenge. This distinction between "causation" and "association" is at the heart of the counter-arguments presented by Tylenol manufacturers and some scientific experts.
The main challenge lies in controlling for confounding factors. For example, a pregnant woman might take Tylenol to relieve fever or pain caused by an infection. It's plausible that the underlying infection itself, or the inflammation it causes, could be linked to neurodevelopmental outcomes, rather than the acetaminophen. Similarly, genetic predispositions play a substantial role in autism and ADHD. As Brian Lee, PhD, an epidemiology professor at Drexel University, highlights, it's crucial to differentiate between merely observing a correlation and proving that one directly causes the other. He notes that the scientific evidence is "shifting strongly towards there being no causal effect."
Ethical considerations also pose a hurdle. It's simply not feasible or ethical to conduct randomized controlled trials where some pregnant women are intentionally given acetaminophen and others a placebo to study long-term effects on their children. Therefore, researchers rely on observational studies, which, while valuable, are more susceptible to confounding variables.
To address these challenges, studies employing sibling comparisons have emerged as a powerful tool. These studies compare children within the same family who share significant genetic material. If an association between Tylenol use and autism disappears when comparing siblings (where one was exposed and the other wasn't, or where exposure differed), it strongly suggests that genetic factors, rather than the drug, are the primary drivers of the outcome. A large Swedish study, involving nearly 2.5 million children, and a Japanese study of approximately 200,000 pregnancies, are examples of such research. Critically, one of the largest studies on the topic, a Swedish sibling comparison study, suggested that Tylenol use during pregnancy does not cause autism, finding no causal link.
These findings contribute to the scientific uncertainty surrounding the issue, making it difficult to definitively conclude a causal link.
The legal journey for claims against Tylenol for autism and ADHD began with individual lawsuits, which quickly escalated into a complex multidistrict litigation (MDL). In October 2022, a federal panel consolidated 65 Tylenol lawsuits from around the United States into an MDL in the United States District Court for the Southern District of New York. The cases were assigned to Judge Denise Cote.
The purpose of an MDL is to centralize similar lawsuits before a single judge to streamline findy and pretrial proceedings, making the process more efficient for all parties involved. This consolidation allowed us to track the rapid growth of these cases. Initially, the request sought to consolidate 19 cases, but more than 30 additional cases were filed shortly after, bringing the total to 49. The numbers continued to climb steadily:
By September 2022, over 500 lawsuits had been filed nationwide against acetaminophen manufacturers and retailers, claiming failure to warn pregnant users about the neurological risks to the fetus.
The pivotal moment in the federal MDL came during the Daubert hearing, a critical legal proceeding where a judge evaluates the scientific validity of expert witness testimony. In August 2024, U.S. District Judge Denise Cote issued a comprehensive 148-page ruling that significantly impacted the litigation. She found that the plaintiffs' expert witnesses "failed to support their conclusions with scientific evidence" linking prenatal acetaminophen exposure to autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). Judge Cote criticized their approach as "unstructured" and "results-driven," noting instances of "cherry-picking" data.
This ruling effectively dismissed the consolidated mass tort litigation, which at its peak involved about 500 lawsuits. The judge's decision means that, unless reversed on appeal, these federal cases cannot proceed to trial. As of November 2025, plaintiffs are actively appealing this decision to the Second Circuit Court of Appeals, with oral arguments set to be heard.
While the federal MDL cases faced dismissal, the legal landscape is not entirely uniform. Some state court lawsuits may still be proceeding independently. For example, a California claim against Johnson & Johnson was dismissed due to state law requiring proof of misrepresentation, whereas a similar claim in Nevada proceeded. This highlights the varying legal standards across states. The Texas Attorney General's lawsuit, filed in 2025, also represents an ongoing state-level legal challenge. We are watching these developments, and you can find the latest information in our Tylenol Autism Update Guide 2025.
As Reuters reported, the judge's decision was a significant victory for Johnson & Johnson and Kenvue, their former consumer health unit, who have consistently maintained that acetaminophen is safe when used as directed.
The recent claims against Tylenol regarding autism and ADHD are not the first time the popular pain reliever has faced legal scrutiny. Johnson & Johnson, the original manufacturer of Tylenol, has a history of defending its product in court against other serious allegations, most notably concerning liver damage.
In the past, Tylenol faced numerous lawsuits alleging that its active ingredient, acetaminophen, caused liver damage and that the product's dosing instructions did not adequately account for the risk of overdose. These liver damage lawsuits often highlighted the narrow therapeutic margin of acetaminophen, meaning there's a fine line between a safe, effective dose and one that can cause severe liver injury.
For instance, Johnson & Johnson was "staring down about 220 lawsuits in state and federal court in New Jersey and Pennsylvania" related to liver damage. In a significant development, J&J scored a victory in the first Tylenol liver-damage case to go to trial in New Jersey. A jury ruled that the plaintiff did not prove she had taken the painkiller as claimed, as reported by Fierce Pharma.
In response to concerns about overdose and liver injury, Johnson & Johnson voluntarily changed the dosing instructions for Extra Strength Tylenol in 2011, reducing the maximum daily dose from 8 pills a day to 6. This action was taken to "help encourage appropriate acetaminophen use and reduce the risk of accidental overdose." Acetaminophen overdose remains a serious public health concern, being the top cause of liver failure in the United States and the second leading reason for liver transplants worldwide, leading to tens of thousands of emergency room visits and hundreds of deaths annually.
This history of litigation underscores the ongoing challenges manufacturers face in balancing product efficacy with clear communication of potential risks to consumers. For a broader overview of legal actions related to this product, explore our Tylenol Lawsuit guide.
The ongoing claims against Tylenol have significant potential financial implications, not just for the manufacturers but also for individuals who believe they have been harmed. While the federal MDL has seen a setback, the pursuit of justice continues through appeals and potential state-level actions.
Even with the recent dismissals in the federal MDL, individuals in California may still be exploring their legal options. We at Justice Hero can help you understand if you meet the criteria that typically determined eligibility for a Tylenol autism lawsuit:
If you believe you meet these criteria and are located in California, consult with a legal professional. Our Tylenol Autism Lawyer page offers resources and guidance to help you steer this process.
The potential financial implications for both manufacturers and consumers involved in claims against Tylenol are substantial. For manufacturers like Johnson & Johnson and Kenvue, the litigation represents a significant financial risk. Had the MDL proceeded to trial or settlement, the potential payouts could have been enormous, with global settlements potentially reaching billions of dollars. The news of the federal MDL dismissal, for example, saw Kenvue's shares rise, indicating the market's relief over avoiding costly litigation.
For individual plaintiffs, if cases were to be successful, the potential compensation could cover a wide range of damages. While there is no definitive settlement or verdict amount given the current legal status, based on experience with similar pharmaceutical liability cases, individual plaintiffs could potentially receive hundreds of thousands of dollars. The value of each claim would depend on several factors, including:
We have comprehensive resources, such as our Tylenol Autism Lawsuit Payout Guide and Tylenol Autism Lawsuit How Much Money, that dig deeper into these potential financial aspects.
Beyond the courtroom, regulatory bodies like the FDA play a crucial role in overseeing drug safety and informing the public about potential risks. Their actions provide important context to the ongoing claims against Tylenol.
The U.S. Food and Drug Administration (FDA) has been actively monitoring the evolving scientific evidence regarding acetaminophen use during pregnancy. In September 2025, the FDA took a significant step by sending a letter to doctors nationwide, warning of a potential connection between Tylenol use during pregnancy and the development of autism and ADHD in children. The letter specifically noted that the risk "may be most pronounced when acetaminophen is taken chronically throughout pregnancy."
Furthermore, the FDA has initiated a label change process for acetaminophen products to reflect this emerging evidence. However, it's important to understand the nuance in the FDA's stance: while acknowledging a "considerable body of evidence" describing an association, the agency explicitly states that "a causal relationship has not been established."
FDA Commissioner Marty Makary emphasized the "precautionary principle," suggesting that many pregnant individuals might choose to avoid acetaminophen, especially for low-grade fevers that don't require treatment. However, he also clarified that it "remains reasonable... for pregnant women to use acetaminophen in certain scenarios." This is because acetaminophen remains the only over-the-counter (OTC) drug approved for use to treat fevers during pregnancy and is generally considered the safest OTC analgesic option compared to alternatives. The FDA is actively seeking public comment on the proposed label change, demonstrating its commitment to transparent regulation. You can find more details on this process through the FDA Request for Comment.
The discussion around claims against Tylenol and its use during pregnancy must also consider the potential health risks of not treating pain and fever. Pregnant women often experience various aches, pains, and fevers, and leaving these conditions untreated can pose significant risks to both the mother and the developing fetus.
High fevers in pregnant women, for instance, are a recognized risk factor for certain birth defects, such as neural tube defects, and can also lead to other complications for the mother. Untreated severe pain can cause maternal stress, which itself can have adverse effects on pregnancy outcomes.
When it comes to pain and fever relief during pregnancy, the options are limited. While acetaminophen is under scrutiny, other common OTC pain relievers like aspirin and ibuprofen have well-documented adverse impacts on the fetus and are generally advised against. Aspirin, for example, can cause bleeding complications, and non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen can lead to fetal organ damage, particularly in the later stages of pregnancy. This makes acetaminophen a crucial tool for managing pain and fever when necessary, highlighting the delicate balance healthcare providers and expectant mothers must strike. It underscores the FDA's cautious approach: acknowledging potential associations while also recognizing the critical need for safe and effective treatment options during pregnancy.
Navigating the complexities of claims against Tylenol can raise many questions. Here, we address some of the most common inquiries we hear from individuals seeking clarity.
No, the federal Tylenol autism lawsuits have not been settled. In fact, the Multidistrict Litigation (MDL) cases, which consolidated hundreds of lawsuits, were dismissed by Judge Denise Cote in August 2024. This dismissal was due to the judge's finding that the plaintiffs' expert witnesses failed to provide sufficient scientific evidence to support a causal link between prenatal acetaminophen exposure and autism or ADHD. However, this is not the final word. The plaintiffs are actively appealing this decision to the Second Circuit Court of Appeals. Therefore, while the federal cases are currently dismissed, the legal battle continues, and no global settlement has been reached. It's also worth noting that some state court cases, like the ongoing Texas Attorney General's lawsuit, may still be active.
According to the FDA and the medical community, Tylenol (acetaminophen) is generally considered the safest over-the-counter pain reliever and fever reducer for pregnant women when used as directed. However, the FDA has acknowledged the emerging scientific evidence suggesting a potential association between chronic prenatal acetaminophen use and an increased risk of autism and ADHD. In response, the FDA is initiating a label change process to include information about these potential risks. Despite this, the FDA emphasizes that a definitive causal relationship has not been established. Our recommendation, consistent with medical advice, is always to use the lowest effective dose for the shortest possible time and to consult with your doctor or healthcare provider before taking any medication during pregnancy.
If you are in California and took Tylenol while pregnant, and your child has since been diagnosed with a neurodevelopmental disorder like autism or ADHD, we understand you may have concerns and questions. Here are the steps we recommend:
The landscape of claims against Tylenol is complex and continuously evolving. While the federal Multidistrict Litigation saw a significant setback with the dismissal of hundreds of cases, the legal battle is far from over. Plaintiffs are vigorously pursuing appeals to the Second Circuit Court of Appeals, and state-level lawsuits continue to emerge, reflecting the ongoing commitment of families seeking answers and accountability.
This litigation underscores the critical importance of scientific evidence in product liability cases and the challenges inherent in establishing causation for complex medical conditions. It also highlights the crucial role of regulatory bodies like the FDA in adapting drug labeling to reflect emerging research, even when a definitive causal link remains unestablished.
For manufacturers, the long shadow of these claims emphasizes the need for rigorous product safety evaluation and transparent communication of potential risks. For consumers, particularly expectant mothers, it reinforces the importance of informed decision-making regarding medication use during pregnancy, always in consultation with healthcare providers.
At Justice Hero, we remain dedicated to simplifying complex legal topics and empowering individuals to seek justice. If you need to understand your legal options regarding the Tylenol and autism lawsuits, particularly if you are in California, we encourage you to explore our comprehensive guide and contact us for a confidential consultation. We are here to help you steer these challenging waters.
